Ezabenlimab clinical trials
Ezabenlimab is named as an intervention in 10 current clinical trials in our USA, Japan, Spain, Germany, Belgium, France, South Korea, Switzerland, Netherlands, UK, Taiwan, China, Italy, Czechia, Brazil, Mexico, Australia, Israel and Canada registers. 4 are recruiting patients now. All registered phases are Phase 1. The sponsor with the most trials is Boehringer Ingelheim (8). The most-studied condition is Solid Tumors. The EU clinical trials register (CTIS) separately lists 1 authorised or ongoing trial.
How Ezabenlimab works
All drug targets →- MyxofibrosarcomaPhase 3
- Soft tissue sarcomaPhase 3
- Undifferentiated pleomorphic sarcomaPhase 3
- Anal squamous cell carcinomaPhase 2
- Biliary tract cancerPhase 2
- CancerPhase 2
- Esophageal squamous cell carcinomaPhase 2
- Non-small cell lung carcinomaPhase 2
- Triple-negative breast carcinomaPhase 2
- Bile duct cancerPhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL4802172, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Ezabenlimab
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of Ezabenlimab
10 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Ezabenlimab in the EU trials register (CTIS)
1 trialAuthorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Ezabenlimab. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.
| Study | Phase | Status | Sponsor | Countries |
|---|---|---|---|---|
|
A phase II trial evaluating treatment intensification with Ezabenlimab in patients with PD-L1–expressing, locally advanced head and neck squamous cell carcinoma (LA-HNSCC) with minimal residual disease (MRD) as detected by circulating tumor DNA (ctDNA) after curative-intent chemoradiation
2025-523575-36-00 · CTIS ↗ · Neoplasms
|
Phase 2 | Authorised | Cliniques Universitaires Saint-Luc | Belgium |
Conditions studied with Ezabenlimab
16 conditionsAll 16 conditions
| Condition (as registered) | Trials |
|---|---|
| Solid Tumors | 2 |
| Pancreatic Ductal Adenocarcinoma | 1 |
| Neoplasms | 1 |
| Colorectal Cancer | 1 |
| MSS | 1 |
| Stage IV Colon Cancer | 1 |
| Stage IV Rectal Cancer | 1 |
| Advanced Solid Tumour | 1 |
| Advanced Solid Cancer | 1 |
| Metastatic Solid Cancer | 1 |
| Glioblastoma | 1 |
| Small Cell Lung Carcinoma (SCLC) | 1 |
| Neuroendocrine Neoplasms | 1 |
| Carcinoma, Squamous Cell of Head and Neck (HNSCC) | 1 |
| Melanoma | 1 |
| Non-small Cell Lung Cancer (NSCLC) | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Boehringer Ingelheim | 8 |
| Amal Therapeutics | 1 |
| Johann Wolfgang Goethe University Hospital | 1 |
By country register
A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.
Related compounds
Questions about Ezabenlimab trials
How many clinical trials are testing Ezabenlimab?
10 current trials in our USA, Japan, Spain, Germany, Belgium, France, South Korea, Switzerland, Netherlands, UK, Taiwan, China, Italy, Czechia, Brazil, Mexico, Australia, Israel and Canada registers name Ezabenlimab (also registered as BI 754091) as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are Ezabenlimab trials recruiting patients?
Yes. 4 of the 10 trials are recruiting: 3 with sites in USA, 3 with sites in Japan, 3 with sites in Spain, 1 with sites in Germany, 1 with sites in Belgium, 1 with sites in France, 1 with sites in South Korea, 1 with sites in UK and 1 with sites in Taiwan. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Ezabenlimab clinical trials?
Boehringer Ingelheim (8), Amal Therapeutics (1) and Johann Wolfgang Goethe University Hospital (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Ezabenlimab works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Ezabenlimab works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Ezabenlimab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.